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Generic substitution is prevalent in the U.S.; however, clinicians and patients remain 
wary of use of generic products for drugs with narrow therapeutic indices. Epileptic 
seizure control is an example of a condition which requires consistent blood 
concentrations of medications; this cannot be assured when patients switch among 
medications from different manufacturers and even between product lots.  
 
Objective 
We aimed to quantify the transient risk of seizure activity attributable to refills and 
switches of phenytoin from same and different manufacturers. 
 
Methods 
We conducted a case-crossover study using administrative claims from the Truven 
MarketScan Commercial Claims and Encounters database in 2010-2012. We 
identified individuals who had at least 1 emergency room visit or hospitalization with 
a primary diagnosis of epilepsy or seizure. We required the cases to have epilepsy and 
at least 2 phenytoin prescription dispensed during the 6-months enrollment in their 
insurance plan before the first observed emergency room visit or hospitalization 
(index date). The case period was defined as the 7 days prior to the index date and the 
control period as 7 days prior to the case period. We used conditional logistic 
 ii 
 
regression to estimate the odds ratio. 
 
Results 
We identified 717 eligible individuals and 143 were discordant cases contributing to 
the analysis. 38% were females and the median age was 48 years old (interquartile 
range (IQR) 18 years). Individuals, who refilled phenytoin of the exact same dosage 
form and strength by the same manufacturer, had a 67% higher odds [odds ratio (OR) 
1.67; 95% confidence interval (CI) (1.14-2.44)] of seizure-related events, when the 
prescription was filled in the 7 days prior to the index date rather than earlier. 
Individuals who switched phenytoin products had a non-significant 21% increased 
odds [OR 1.21; 95% CI (0.60-2.46)] of an event. The refill-adjusted risk for switching 
was close to the null [OR 0.73; 95% CI (0.33-1.63)]. 
 
Conclusions 
Our results suggest that the period after refills and switches may be a high risk period 
for epileptic patients. Equal attention should be given to the cautious monitoring after 
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  To balance the increasingly heavy economic burden of healthcare and gradually 
increased patients needs, generic substitution has been prevalently used in the US. In 
2013, 86 percent of all prescriptions filled in the U.S were generic drugs. According 
to the legislation in 1984, there are 12 states where generic substitution is mandatory 
by law.1 
  To ensure the bioequivalence to their innovators, FDA requires generic drug 
manufacturers to prove their products have equivalent bioavailability. FDA guidance 
has recommended that the confidence intervals for the area under the curve (AUC) 
and maximum concentration (Cmax) of the generic drug should be within 80% to 125%  
of the confidence intervals of branded drug after log transformation, within which the 
difference in blood concentration for most drugs is considered not to be clinically 
significant.2  
  Despite of the stringent requirements by licensing agency, several surveys showed 
negative perceptions of generic drugs from consumers and prescribers for its efficacy 
and safety issues.3-7 This kind of concern is especially greater for drugs with narrow 
therapeutic index (NTI), of which small variation in dosage may result in a lack of 
efficacy or toxicity.  
  Phenytoin, as one of the mainstream antiepileptic drugs (AEDs), is commonly 
considered as an NTI drug. A slight change in its absorption will result in great 
adverse health outcomes.8-9 Besides, it has the characteristics of low water solubility 
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and non-linear pharmacokinetics, all risk factors to increase the likelihood of 
fluctuation in serum concentration and incidence of uncontrolled seizures when there 
is minor products change.10 
  As the fourth most common neurological disorder in the United States after migraine, 
stroke, and Alzheimer’s disease, epilepsy is a complex spectrum of disorders that 
affects people of all ages. According to a report issued by IOM 2012, 2.2 million people 
in the United States have epilepsy. Each year 150,000 new cases of epilepsy are 
diagnosed and 1 in 26 people in the United States will develop epilepsy at some point in 
their lifetime.11 A study in 2008 showed seizure accounts for 1 million Emergency 
Department (ED) visits annually [95% confidence interval (CI)  (926,000–1,040,000)], 
or 1% of all ED visits in the US.12 The contribution of “breakthrough seizures” among 
chronic epileptic patients to the burden of seizure care in the ED setting is unknown. 
A study suggested that only 6.8% of seizures in the ED were due to epilepsy.13 
However, a smaller study in a different setting found that 46% of seizure visits to an 
urban ED were by individuals with known epilepsy.14 
  Although epilepsy is a chronic disorder that may not be cured, it can be controlled. 
The ultimate goal of treatment is to maintain the patients’ normal lifestyle and reduce 
the epilepsy-related morbidity and mortality by the avoidance of seizures. Recent 
studies have shown that up to 70% of newly diagnosed individuals with epilepsy can be 
successfully treated (i.e. completely controlled seizures) with AEDs.15 When the 
long-term remission has been obtained, it becomes important to avoid even a single 
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breakthrough seizure. Previous studies showed that after a period of control, just a 
single breakthrough seizure can have great impact on patients’ social and personal life, 
like loss of employment, loss of self-esteem, and even risk of death.16-28 Therefore, 
epileptic treatment may have higher risk of negative health consequences when there is 
any slight loss of efficacy by changing product.10 
  Corresponding to the above mentioned aspects, the American Academy of 
Neurology opposes antiepileptic generic substitution without physician approval.29 
Breakthrough seizures have been attributed to switching prescriptions between 
brand-name and generic phenytoin.30 In case reviews, participated in by sixty-nine 
physicians, fifty of their patients, whose conditions were well-controlled on a 
brand-name antiepileptic drug, subsequently experienced a breakthrough seizure or 
increased seizure frequency after switching to a generic without other provoking 
factors.31 Inconsistent evidence emerged from observational studies and clinical trials. 
The retrospective studies showed a significant association between generic 
substitution and increased utilization of healthcare sources, while prospective trials 
showed no significant difference in seizure frequency between brand-name and 
generic drugs.32-33 
  The risk was not only elevated when patients switched among medications from 
different manufacturers but even when refilled between different product lots from the 
same manufacturer. A case-crossover was conducted by Gagne et al in 2010 to 
evaluate the risk for breakthrough seizures associated with both refilling and 
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switching. In their study, switching was treated as a special case of the refilling 
process. Enabled by the unique study design, they showed that refilling itself 
significantly increased the transient risk of seizure-related events. An elevated risk 
was also observed in switching, but the association was no longer significant in this 
much smaller group. And the risk was similar after comparing the risk for switching 
to that for refilling.34 
  In this study we aimed to use a standard unidirectional case-crossover design to 
quantify the transient risk of seizure activity attributable to refills and switches of 
phenytoin from same and different manufacturers and of same or different dosage 
form and strength. We first tested the hypothesis that patients, who refill a phenytoin 
product of the exact same dosage form and strength by the same manufacturer, have a 
higher risk of seizure-related emergency room visits or hospitalizations when the 
refilling occurs during the case period than during the control period. We further 
tested the hypothesis that patients who switch to a phenytoin product of different 
dosage form, strength or manufacturer have a higher risk of seizure-related outcomes 
when the switching occurs during the case period than during the control period. At 
last, we examined the hypothesis that the risk associated with switching is greater 






2 Methods  
2.1 Data source 
  We used Truven Health MarketScan Commercial Claims and Encounters Database 
from 2010 to 2012. It contains data from active employees, early retirees, 
Consolidated Omnibus Budget Reconciliation Act (COBRA) continuees, and 
dependents insured by employers-sponsored plans (i.e., persons not eligible for 
Medicare) in the United States. The dataset captures individual-level information 
about clinical utilization, expenditures and enrollment across inpatient, outpatient and 
prescription drug services in all 8 tables. Patients were identified in inpatient 
admission table and outpatient services table, which contain data including diagnostic 
codes and date on which service incurred. An outpatient pharmaceutical claims table 
was also used to identify medication refill records. All tables used were linked by a 
personal enrollment identification number unique to each enrollee. The MarketScan 
data are completely de-identified to protect patient confidentiality; their use is 
considered exempt from review by institutional review board of the Johns Hopkins 
Bloomberg School of Public Health.35 
2.2 Study Design 
  A case-crossover (CCO) study was used to examine the relationship between the 
seizure-related emergency room visits or hospitalization and phenytoin refilling and 
switching. CCO is a retrospective observational study. It is a kind of case-only design 
which restricts to cases, that is, only people who experienced the outcome of interest 
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at least once during the follow-up were included in the study. The term “crossover” is 
used because the analysis is restricted to people who had both exposed and unexposed 
person-time and therefore crossed between two or more exposure levels.36 Instead of 
selecting matched controls based on some measured covariates or time points, CCO 
uses cases as their own controls, by assuming an exposure risk window proximate to 
the event as the case period and the time beyond (either earlier or even after the event) 
as the control-period. The investigator then compares the exposure distribution in the 
case periods to the control periods. The CCO method has been commonly used to 
assess the transient effects of eruptive or intermittent exposure like prescription 
refilling and switching, or vaccination. This design by nature accounts for the 
measured and unmeasured time-invariant confounders such as sex and race, and some 
time-variant but not fast-changing confounders like age would be weak enough to be 
ignored if the exposure risk window is very short and the case period is close to the 
control period.37-39  
  In our study, we used a standard CCO, in which time was viewed relative to the 
date of the outcome event and only one control-period was selected from the time 
before the case-period. 
2.3 Study population  
  We started by identifying patients who had at least one emergency room visit or 
hospitalization with a primary diagnosis of International Classification of Disease, 
Ninth Revision, Clinical Modification (ICD-9) codes 345.xx (epilepsy and recurrent 
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seizures) or 780.3x (convulsions), but not code 345.6x (infantile spasms), between 
2010 and 2012 in the outpatient or inpatient data files. The first identified 
hospitalization or emergency visit was considered to be the index date for all analyses. 
Individuals whose index date was in the first 6 months in 2010 were excluded to 
ensure that exposure and covariates data were available for the 180 days prior to the 
index date for each case. To make sure that phenytoin was used for treatment of 
epilepsy, rather than prevention of seizures such as after surgery or trauma, we further 
required individuals to have had at least one outpatient visit (not to emergency rooms) 
with the above mentioned ICD-9 codes prior to the index date. Lastly, we required at 
least two prescriptions of anticonvulsant hydantoin derivatives dispensed on separate 
days during the 180-days of constant enrollment prior to the index date. Relevant 
medications were identified by their National Drug Classification (NDC) codes. 
Patients who were concurrently using a medicine from a different class of AEDs but 
who did not initiate, terminate, or change the medicine during the case and control 
periods were included in the study. Patients with changes in these other AEDs 
medications in the relevant time periods were excluded. A grace period of 2 days was 
granted to the gap between the two refills and the patients who had a medication 
discontinuation larger than 2 days were excluded from the analysis. 
2.4 Case and control periods definition 
  In the primary analysis, for both refilling and switching, we defined a 1-day 
induction period as the minimum time needed to experience a seizure-related outcome 
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(one emergency room visit or hospitalization with a primary diagnosis of epilepsy or 
seizures) after the exposure in the population, which was consistent with a former 
study.34 We used a prespecified 7-day risk window immediately preceding the 
induction period as the case period and another 7-day risk window right before the 
case period as the control period (Figure 1). This was chosen based on the 
pharmacokinetics characteristics of phenytoin and a study in the past.40-41  
2.5 Exposure definition 
  A refill was defined as a filled phenytoin prescription for a given NDC code that 
was preceded by a filled prescription with the identical NDC code, indicating 
dispensing a phenytoin product of the same dose and strength by the same 
manufacturer. A switch was defined as a filled phenytoin prescription with a given 
NDC code that was preceded by a filled prescription for the same medication but with 
a different NDC code, indicating dispensing a phenytoin product of a different dose, 
strength or manufacturer. The date of refilling or switching was defined as the date of 
dispensing the second or subsequent prescription and it must be covered by the 
previous prescription. Days-covered by a prescription was defined as the date of 
refilling or switching of a prescription plus its days supply plus a 2-day grace period. 
Branded and generic phenytoin were distinguished by a generic drug indicator 
variable in the MarketScan data. 
2.6 Confounders definition 
  To control for the confounding by indication in the observational study, the number 
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of visits to neurologists was used as a proxy for the disease severity of epilepsy and 
measured in both case and control periods. Another important source of confounding 
was the drug and drug interaction. The interaction caused by the concurrent initiation 
or termination of other classes of AEDs during the case and control periods was 
handled by the restriction in study design; the concurrent initiation or termination of 
medication for non-epileptic conditions (i.e. Non-AEDs) was controlled in the 
analysis. It was identified by different values of a therapeutic class variable between 
the two refills. This therapeutic class variable is a 3-digit code that indicates the 
therapeutic/pharmacologic category of the drug product based on the American 
Hospital Formulary Service Classification Compilation (AHFSCC) Therapeutic Class 
with a range of value from 1 to 999. 
2.7 Statistical methods 
  Conditional logistic regression was used to calculate the risk of seizure-related 
outcomes associated with phenytoin refilling and switching before and after 
controlling for the confounding by physician visits and concurrent medications 
change of Non-AEDs, under the assumption that they were not affected by their 
previous status.42 The dependent variable in the model followed a binomial 
distribution and was given a value of 1 for case period and 0 for control period. The 
independent variable, “exposure”, was a dichotomous indicator for exposure status, 
which was given a value of 1 when a refill or switch occurred and a value of 0 when 
neither refill nor switch occurred during the case or control period. An interaction 
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term between “exposure” and “group” was also added to the right side of the model, 
where “group” was a dichotomous indicator for switching status, and had a value of 1 
when a switch occurred and a value of 0 when a refill occurred during the case or 
control period; Thus the coefficient of “exposure” was an estimate of the odds ratio 
(OR) of seizure-related outcomes associated with refilling only, and the summation of 
the coefficients of “exposure” and “group” was an estimate of the OR of 
seizure-related outcomes associated with switching alone, on log scale. The use of this 
product term enabled us to adjust for the within-manufacturer between-lot variability 
and other factors involved in the prescription refilling or switching process and 
generated a refill-adjusted estimate of the risk of seizure-related outcomes associated 
with switching. Number of physician visits to neurologists was included to the 
adjusted model as an ordinal variable and concurrent medication change of 
Non-AEDs was included as a binary variable. The performances of crude and 
adjusted models were compared by Likelihood Ratio Test (LRT). Statistical packages 
SAS 9.3 and STATA 12.0 were used for all the analyses. 
2.8 Sensitivity analysis  
  For sensitivity analyses, we first varied the case and control periods from 7 days to 
10 days. The grace period was not extended because we believed that any gap greater 
than 2 days between 2 sequential refills would lead to a substantial change in blood 
concentration of phenytoin and that subsequent seizures would be attributable to 
medication non-adherence. This stringent definition of medication compliance was 
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chosen based on the narrow therapeutic range of phenytoin.41 Secondly, we limited 
the analysis to individuals using phenytoin as monotherapy during the case and 
control periods, that is, patients who did not have concurrent AEDs in other classes. In 
the third sensitivity analysis, we adjusted the dates of refilling or switching for the 
stacked (or left-over) pills among patients who refilled or switched while there was 
still medication on hand from the previous prescription. Lastly, we excluded the 


















  A total of 717 cases were identified in the MarketScan data. Their characteristics 
are summarized in Table 1. The patients were predominantly middle-aged men who 
had one physician visit to their neurologists and one phenytoin prescription dispensed 
during the case and control periods. As in a matched case-control study, only the 
cases with discordant exposure status between the case and control periods 
contributed information to the analysis. Therefore, 143 of 717 individuals were 
included in the primary analysis. The majority were also middle-aged men, who had 
one phenytoin dispensed, but most of them didn’t have any concurrent medication 
change of non-AEDs or physician visits to their neurologists during the periods (Table 
1). The distribution of phenytoin refills and switches in the 180 days prior to the index 
date was shown in Figure 2 and 3. Only the refill or switch closest to the index date of 
each 717 individual was counted.  
  The results of our primary analyses are shown in Table 2. Both individuals who 
refilled phenytoin and those who switched among phenytoin products within the case 
window had increased odds of a seizure-related emergency room visit or 
hospitalization relative to those who refilled or switched outside of the case window. 
In the crude analysis, the OR related to a refill alone was 1.67 with 95% CI (1.14-2.44) 
and for a switch alone the OR was 1.21 [95% CI (0.60-2.46)].  
  Accounting for the risk associated with a refilling process, i.e., between-lot 
variability and other factors, a medication switch had 0.73 times the risk of 
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seizure-related outcomes than the risk associated with refilling and the 95% CI for 
this refill-adjusted OR was (0.33-1.63).  
  In the adjusted analysis, after controlling for two confounders, the OR related to 
refilling decreased to 1.47 [95% CI (0.93-2.30)]. The OR associated with switching 
also declined to 1.10 [95% CI (0.53-2.29)]. The refill-adjusted OR was 0.76 [95% CI 
(0.33-1.69)], quite close to the crude analysis. The likelihood ratio test indicated that 
the adjusted model fit no better than the crude model (p=0.56), so only unadjusted 
models were used in the subgroup and sensitivity analyses below. 
  Regardless of whether the refill was a refill of a branded product or a refill of a 
generic phenytoin product, the risk of seizure-related outcomes was higher when the 
refilling occurred during the 7-day case period than during the 7-day control period, 
but this relationship was only statistically significant for the more prevalent generic 
refilling. For different subcategories of switching, the highest risk, an OR 3.00 [95% 
CI (0.61-14.86)], was observed for individuals switching between different generic 
products. The risk was also elevated for those switching from a generic product to a 
branded phenytoin, with an OR of 1.25 [95% CI (0.34-4.65)]. ORs of 0.83 [95% CI 
(0.25-2.73)] and 0.50 [95% CI (0.05-5.51)] were seen, respectively, among 
individuals switching between branded phenytoin products, and switching from a 
branded product to a generic phenytoin (Table 3). 
  Table 4 includes all the results from our sensitivity analyses. After extending the 
risk period from 7 to 10 days, a similar increased risk was observed. The OR for 
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refilling alone was 1.40 [95% CI (1.01-1.93)] and for switching alone 1.11 [95% CI 
(0.59-2.10)]. The refill-adjusted OR was 0.79 [95% CI (0.39-1.59)].  
  By excluding the individuals that were on other classes of AEDs along with 
phenytoin during the case or control period, the OR among individuals on phenytoin 
monotherapy was 1.46 [95% CI (0.96-2.22)] for refilling and 1.00 [95% CI 
(0.43-2.31)] for switching, when the 7-day risk windows were used in case and 
control periods. The refill-adjusted OR was 0.69 [95% CI (0.27-1.74)]. Comparable 
results were seen when 10-day risk windows were applied.  
  We also adjusted the date of refilling or switching from the actual refill or switch 
date, on which a patient filled his/her prescription at pharmacies, to the date, on which 
the last dose of his/her previous prescription was supposed to be taken, if the patient 
refilled or switched phenytoin earlier than the day of last dose. Refilling alone was 
associated with 1.09 [95% CI (0.86-1.38)] times risk of seizures-related outcomes and 
switching alone was associated with 0.82 times of the risk of refilling [95% CI 
(0.41-1.65)], when 7-day risk windows were used, and similar results were observed 
in 10-day risk periods. 
  Last, after excluding cases whose refill or switch involved a change in dosage form 
or strength or both, the OR for seizure-related outcomes associated with refilling 
alone was 1.67 [95% CI (1.14-2.44)] and 1.50 [95% CI (0.25-8.98)] for switching 
alone, when using 7-day risk windows. The refill-adjusted OR was 0.90 [95% CI 
(0.14-5.61)]. In 10-day risk windows, the OR for a refill was 1.40 [95% CI 
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(1.01-1.93)] and a switch was 2.00 [95% CI (0.37-10.92)]. The refill-adjusted OR 
increased to 1.43 [95% CI (0.25-8.06)]. Although the point estimates of refill-adjusted 
OR for switching were seen on different sides of 1 depending on the length of the risk 




















4 Discussion  
  In this study, we found that individuals, who refilled a phenytoin product of the 
exact same dosage form and strength by the same manufacturer, were at a 67% 
increased risk of seizure-related events during a short period after refilling than the 
time beyond during which they continued taking their current prescription. Although 
after adjustment for plausible confounders, this point estimate was no longer 
statistically significant and moved towards the null with a widened confidence 
interval, the LRT test gave more credibility to the results from the crude analysis and 
it supported a statistically increased risk associated with refilling. A similarly elevated 
risk, albeit with a wide confidence interval, was also seen when switching to a 
phenytoin product of different dosage form, strength or manufacturer. After 
accounting for the risk associated with refilling process, switching alone did not pose 
additional increased risk of seizure-related outcomes, for the refill-adjusted OR was 
around 1.  
  The possible mechanism for this observation was proposed in a previous study by 
Gagne et al in 2010. Two of main explanations they discussed were the within- and 
between-manufacturer variability in bioavailability and the patients’ behavioral 
aspects which trigger pharmacotherapy discontinuity.34 The between-manufacturer 
variability between approved generic drugs and their innovators has been reviewed in 
a study funded by the US Food and Drug Administration (FDA) in 2009. 
Bioequivalence was measured by the evaluation of Cmax and AUC, 
 16 
 
representing drug rate and extent of absorption. A small difference was found. The 
average difference of Cmax and AUC between generic drugs and their innovators was 
4.35% and 3.56%, respectively.46 However, some researchers argued that 
bioequivalence implies but does not guarantee that a drug will have the same 
therapeutic and adverse effects as the reference drug, due to the permitted range of 
bioavailability for generics, small numbers of relatively young healthy volunteers in 
the evaluation methods as well as individual variation in the response to the drug.20 
Similar fluctuations in the bioavailability and other attributes may be expected 
between different lots of an identical product manufactured by the same company.47-50 
Patients are also vulnerable to non-adherence during the refilling and switching 
process; confusion and mistrust caused by the change of drug appearance may lead to 
medication discontinuation and result in breakthrough seizures.43-45  
  Our results are consistent with the study by Gagne et al., but their results showed a 
greater magnitude of risk, in which refilling alone was associated with around 2.1- to 
2.3- fold increase in the odds of seizure-related outcomes, and a 4% to 19% increase 
in risk associated with the refill-adjusted effect of switching between products from 
different manufacturers. However, there are several differences between these 2 
studies that should be noted. Their study was conducted using an administrative 
database from Canada with data from 1996-2005. Different manufacturing practices 
in 1990s may prevent the application of their results to the patients today. Besides, the 
utilization patterns in their study were very different from what we observed in the US 
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dataset. In our data, most patients received 30-day supplies of the drug; the majority 
of their prescriptions fills were with 90-day supplies. This enabled them to have the 
power to examine the relationship in a much longer risk window, 21/28 days, 
compared to the 7 days in our study. Their study population was older and had more 
females than our study. Moreover, as they mentioned in their paper, the 
bioequivalence requirements of the US FDA are more stringent than those of Health 
of Canada. The requirements established by FDA was intended to ensure that the 
differences in bioavailability between bioequivalent products, i.e., the 
between-manufacturer variation are no greater than between-lot within-manufacturer 
variation.51-52 This would result in our seeing fewer difficulties at the time of refill 
than what was seen in the Canadian study. Besides, Gagne et al included refilling and 
switching of multiple classes of antiepileptic drugs with different pharmacokinetic 
characteristics and the 21/28-day risk window was applied despite of classes.34 They 
also defined “switch” more strictly than we did since they required the dosage form 
and strength to be held constant, so cases who switched could only be included if the 
product came from different manufacturers. Other similar results to the risk for 
switching was found in a nested case-control study, in which a crude OR of 1.51 [95% 
CI (1.29-1.76)] and an adjusted estimate of 1.08 [95% CI (0.91-1.29)] were 
calculated.53  
  There are several limitations we would like to point out in our study. First, by using 
ICD-9 codes from emergency room visits and hospitalizations to identify our cases, 
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only the breakthrough seizures severe enough to require inpatient care were recorded; 
seizures at home would not be captured. The accuracy or correctness of the 
ICD-codes recorded by healthcare providers is unknown but is likely to be highly 
sensitive and specific in a population of patients with epilepsy. The record of a 
patient’s refilling or switching in the claims data does not necessarily indicate what 
the patient was taking and how complete was his/her adherence. Even if a patient 
refilled medication at the end of previous prescription, he/she may not take the 
medication immediately. Lastly, the size of our study population was relatively small, 
especially the group that switched among products. This lack of power brought wide 
confidence intervals to our estimation and added more uncertainty to some of our 
results.   
  However, our study also has the following strengths. Although our sample size was 
relatively small, we began with a claims data from 70 million individuals. It is 
unlikely that other data would allow investigator to identify many more patients 
meeting the specified criteria. We chose to use a case-crossover design, which is 
considered to be efficient on its own. According to a review by Maclure et al., fewer 
than half as many subjects may be needed in a case-crossover study as in a traditional 
case-control study because the same results may be obtained without the need to 
select traditional controls and each case can provide at least one control time.38 
Another difference from the traditional case-control study is its unidirection design, in 
which the control period is selected to be before the time of the case period only, 
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which makes the results less affected by reverse causality.36 Although this design is 
susceptible to exposure-trend bias, our decision to use a short risk window in the case 
and control periods, as well as their close placement to each other, should make this 
risk negligible. Our selection of one single control-period from the time before the 
case-period was the most efficient control sampling strategy in terms of our 
prespecified length of the risk window and induction period, the degree of 
within-person confounding and the quality of data available.54 Our study more 
carefully controlled for the confounding from drug-drug interactions by taking the 
termination of a drug into consideration, apart from initiation. In our study, only one 
class of anti-epileptics was studied and the prespecified risk-window was defined 
based on the drug’s pharmacokinetic characteristics, hopefully reducing 
misclassification of the exposures.40 This single class design also prevented the 
transient effect of refilling or switching from being offset by variations of 
pharmacological characteristics among different classes, if the effects of these 
variations were in opposite directions. Despite of the relatively small sample size, 
there was no empty cell in any subcategory of refilling and switching. This enabled us 
to show the individual risk associated with each subcategory in the subgroup analysis.  
  Based on our findings, we suggest that patients with epilepsy and healthcare 
providers should be cautious during the first 7-10 day after phenytoin refilling and 
switching as this is a higher risk period for severe seizure activity. Clinicians and 
payers should encourage the extension of the commonly prescribed 30 days of supply 
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to 90 days of phenytoin to reduce the refill frequency. The results of our study are 
expected to be relevant to European patients as well, considering the European 
Medicines Agency has the same requirements of bioequivalence as the US FDA.55 
  To conclude, we found an increased risk of seizure-related outcomes when refilling 
a phenytoin product of the exact same dosage form and strength by the same 
manufacturer. Switching to a phenytoin product of a different dosage form, strength or 
manufacturer has much in common with the refilling process and was also found to be 
associated with an elevated risk of seizure-related events. However, extra risk arising 
from between-manufacturer differences, which is a concern of patients and physicians, 


























5.1 Table 1 Characteristics of study population and discordant cases in the 
primary analysis 
Characteristic Study populationa Discordant casesb 
Age at index date, median (IQRc) 48 (18) 47 (19) 
Female, n (%) 271 (37.8%) 49 (34.3%) 
Number of phenytoin dispensed 
during primary 14-day study 
period, median (IQR) 
1 (0) 1 (0) 
No concurrent medication change 
of non-AEDsd during 7-day case 
period, n (%) 
414 (57.7%) 136 (95.1%) 
No concurrent medication change 
of non-AEDs during 7-day control 
period, n (%) 
418 (58.3%) 138 (96.5%) 
Number of physician visits during 
7-day case period, median (IQR) 
1 (0) 0 (0) 
Number of physician visits during 
7-day control period, median 
(IQR) 
1 (0) 0 (0) 
a. Number of study population, Ns=717. 
b. Number of discordant cases contributed to the analysis, Na=143. 
c. IQR, interquartile range. 




















5.2 Table 2 Odds ratios (95%CIs) for the relationship between phenytoin refilling 
and switching and seizure-related outcomes for primary analyses* 
 Crude analysisa Adjusted analysisb 












Refillc 1.67 (1.14-2.44) 1.47 (0.93-2.30) 
Switchd 1.21 (0.60-2.46) 1.10 (0.53-2.29) 
Refill-adjusted odds ratio 
for switching 
0.73 (0.33-1.63) 0.76 (0.33-1.69) 
Number of Physician visits   0.88 (0.33-2.29) 
No concurrent medication 
change of non-AEDse 
  1.39 (0.75-2.58) 
* Ns=717; Na=143. 
a. Unadjusted model in the primary analysis:  
𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 = 𝛽𝛽0 + 𝛽𝛽1 × 𝐸𝐸𝐸𝐸𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂 + 𝛽𝛽2 × 𝐸𝐸𝐸𝐸𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂 × 𝐺𝐺𝐸𝐸𝑂𝑂𝑂𝑂𝐸𝐸. 
b. Adjusted model in the primary analysis: 𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 = 𝛽𝛽0 + 𝛽𝛽1 × 𝐸𝐸𝐸𝐸𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂 + 𝛽𝛽2 × 𝐸𝐸𝐸𝐸𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂 ×
𝐺𝐺𝐸𝐸𝑂𝑂𝑂𝑂𝐸𝐸 + 𝛽𝛽3 × 𝑁𝑁𝑂𝑂𝑂𝑂𝑁𝑁𝑂𝑂𝐸𝐸 𝑂𝑂𝑜𝑜 𝐸𝐸ℎ𝑦𝑦𝐸𝐸𝑦𝑦𝑂𝑂𝑦𝑦𝑦𝑦𝑦𝑦 𝑣𝑣𝑦𝑦𝐸𝐸𝑦𝑦𝑂𝑂𝐸𝐸 + 𝛽𝛽4 × 𝑁𝑁𝑂𝑂𝑦𝑦 − 𝐴𝐴𝐸𝐸𝐴𝐴𝐸𝐸 𝑂𝑂𝑂𝑂𝑚𝑚𝑦𝑦𝑂𝑂𝑦𝑦𝑂𝑂𝑦𝑦𝑂𝑂𝑦𝑦 𝑂𝑂ℎ𝑦𝑦𝑦𝑦𝑎𝑎𝑂𝑂. 
c. Refill of phenytoin for the same strength, and dosage form from the same manufacturer. 
d. Switch to a different strength, dosage form or manufacturer. 























5.3 Table 3 Odds ratios (95%CIs) for the relationship between phenytoin refilling 
and switching and seizure-related outcomes for subgroup analyses * 
Exposure type Na Odds ratio (95% CI) 
  Refill   
    Generic (GG) 74 1.74 (1.08-2.79) 
    Branded (BB) 38 1.53 (0.80-2.94) 
  Switch   
    Generic – Branded (GB) 9 1.25 (0.34-4.65) 
    Branded – Generic (BG) 3 0.50 (0.05-5.51) 
    Generic – Generic (GG’) 8 3.00 (0.61-14.86) 
    Branded – Branded (BB’) 11 0.83 (0.25-2.73) 
* Unadjusted model in the subgroup analysis only: 𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 = 𝛽𝛽0 + 𝛽𝛽1 × 𝐺𝐺𝐺𝐺 𝑦𝑦𝑦𝑦𝑚𝑚𝑦𝑦𝑂𝑂𝑦𝑦𝑂𝑂𝑂𝑂𝐸𝐸 + 𝛽𝛽2 ×

































5.4 Table 4 Odds ratios (95%CIs) for the relationship between phenytoin refilling 
and switching and seizure-related outcomes for sensitivity analyses * 
 Refill Switch Refill-adjusted 






Ns Na Odds ratio 
(95% CI) 
Na Odds ratio 
(95% CI) 
Odds ratio  
(95% CI) 
Extended number of days in case and control periods 

























Adjusted refill/switch dates 












Excluded switches between different dosage forms or strengths 












* Unadjusted model in the sensitivity analysis only: 
𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 = 𝛽𝛽0 + 𝛽𝛽1 × 𝐸𝐸𝐸𝐸𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂 + 𝛽𝛽2 × 𝐸𝐸𝐸𝐸𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂𝐸𝐸𝑂𝑂 × 𝐺𝐺𝐸𝐸𝑂𝑂𝑂𝑂𝐸𝐸. 













6.1 Figure 1 Case-crossover study design*  
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